Parkinson’s cell therapy developer files to go public

T2Covered by 1 source · first reported by BioPharma Dive / Healthcare Dive / MedTech Dive at 12 Oct, 15:58 UTC

Aspen Neuroscience is looking to join the Nasdaq and raise more money to support its lead program, which aims to turn a patient's own cells into dopamine-producing neurons.